JPWO2021020564A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021020564A5
JPWO2021020564A5 JP2021535464A JP2021535464A JPWO2021020564A5 JP WO2021020564 A5 JPWO2021020564 A5 JP WO2021020564A5 JP 2021535464 A JP2021535464 A JP 2021535464A JP 2021535464 A JP2021535464 A JP 2021535464A JP WO2021020564 A5 JPWO2021020564 A5 JP WO2021020564A5
Authority
JP
Japan
Prior art keywords
antigen receptor
chimeric antigen
ganglioside
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535464A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021020564A1 (cg-RX-API-DMAC7.html
JP7505784B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/029446 external-priority patent/WO2021020564A1/ja
Publication of JPWO2021020564A1 publication Critical patent/JPWO2021020564A1/ja
Publication of JPWO2021020564A5 publication Critical patent/JPWO2021020564A5/ja
Application granted granted Critical
Publication of JP7505784B2 publication Critical patent/JP7505784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535464A 2019-08-01 2020-07-31 Gd2結合性分子 Active JP7505784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019142358 2019-08-01
JP2019142358 2019-08-01
PCT/JP2020/029446 WO2021020564A1 (ja) 2019-08-01 2020-07-31 Gd2結合性分子

Publications (3)

Publication Number Publication Date
JPWO2021020564A1 JPWO2021020564A1 (cg-RX-API-DMAC7.html) 2021-02-04
JPWO2021020564A5 true JPWO2021020564A5 (cg-RX-API-DMAC7.html) 2022-06-01
JP7505784B2 JP7505784B2 (ja) 2024-06-25

Family

ID=74228907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535464A Active JP7505784B2 (ja) 2019-08-01 2020-07-31 Gd2結合性分子

Country Status (6)

Country Link
US (1) US20220275104A1 (cg-RX-API-DMAC7.html)
EP (1) EP4008347B1 (cg-RX-API-DMAC7.html)
JP (1) JP7505784B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001649A2 (cg-RX-API-DMAC7.html)
ES (1) ES3031393T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021020564A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7521815B2 (ja) * 2019-08-01 2024-07-24 国立大学法人三重大学 抗原受容体
WO2023081485A1 (en) 2021-11-08 2023-05-11 Pacific Biosciences Of California, Inc. Stepwise sequencing of a polynucleotide with a homogenous reaction mixture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5654986B2 (ja) * 2008-06-30 2015-01-14 モーフオテク・インコーポレーテツド 抗gd2抗体並びにそれに関連する方法及び使用
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EP2614143B1 (en) * 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
KR20230100748A (ko) * 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
EP3600357A4 (en) * 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
CN118853581A (zh) * 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
IT201800007601A1 (it) * 2018-07-30 2020-01-30 Rigenerand Srl Metodo per la produzione di cellule bi-funzionali per il trattamento di tumori
IL288807B1 (en) * 2019-06-13 2026-08-01 Allogene Therapeutics Inc ANTI-TALEN ANTIBODIES AND THEIR USES

Similar Documents

Publication Publication Date Title
Silence et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Sawada et al. Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity
JP2021534802A5 (cg-RX-API-DMAC7.html)
JP2021506244A5 (cg-RX-API-DMAC7.html)
Mittal et al. Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2021522801A5 (cg-RX-API-DMAC7.html)
JP2017513478A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2020527144A5 (cg-RX-API-DMAC7.html)
JP2020517249A5 (cg-RX-API-DMAC7.html)
CN111194323A (zh) 多特异性抗体
JP2019527696A5 (cg-RX-API-DMAC7.html)
JP2019513370A5 (cg-RX-API-DMAC7.html)
JP2015533853A5 (cg-RX-API-DMAC7.html)
JP2009502171A5 (cg-RX-API-DMAC7.html)
JP2019505564A5 (cg-RX-API-DMAC7.html)
JP2017500057A5 (cg-RX-API-DMAC7.html)
KR20170085531A (ko) 항-cldn 키메라 항원 수용체 및 사용 방법
JP2014534242A5 (cg-RX-API-DMAC7.html)
KR20140014064A (ko) 신규한 조절 인자 및 사용 방법
KR20140018837A (ko) 노텀 단백질 조절 인자 및 사용 방법
JP2013527762A5 (cg-RX-API-DMAC7.html)
JP2020534012A5 (cg-RX-API-DMAC7.html)
CN112292399A (zh) 抗cd27抗体及其用途